Affimed N.V. (NASDAQ:AFMD) Q4 2022 Earnings Conference Call March 23, 2023 8:30 AM ET

Company Participants

Alex Fudukidis - Director of Investor Relations

Adi Hoess - Chief Executive Officer

Andreas Harstrick - Chief Medical Officer

Angus Smith - Chief Financial Officer

Wolfgang Fischer - Chief Operating Officer

Conference Call Participants

Daina Graybosch - SVB Securities

Srikripa Devarakonda - Truist

Maurice Raycroft - Jefferies

Li Watsek - Cantor

Operator

Good day, ladies and gentlemen. Thank you for standing by. Welcome to today's Full Year and Fourth Quarter Earnings and Business Update Conference Call by Affimed N.V. [Operator Instructions] Please note, this conference call is being recorded.

I would now like to hand the call over to your host for today, Alex Fudukidis, Director of Investor Relations at Affimed. Please go ahead.

Alex Fudukidis

Thank you, Olivia and thank you all for joining us today for our full year 2022 update call.

Before we begin, I'd like to remind everyone that we issued the relevant press release earlier today which can be found on the Investor Relations section of our website. On the call today, we have the members of our management team, including Adi Hoess, our Chief Executive Officer; Andreas Harstrick, our Chief Medical Officer; Arndt Schottelius, our Chief Scientific Officer; Wolfgang Fischer, our Chief Operating Officer; Denise Mueller, our Chief Business Officer; and Angus Smith, our Chief Financial Officer. The team will be available for the Q&A session after the prepared remarks.

Before we start, I'd like to remind you that today's presentation contains projections and forward-looking statements regarding future events. These statements represent our beliefs and assumptions only as of the date of this call. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. These forward-looking statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied in these statements due to various factors, including but not limited to, those identified under the section entitled Risk Factors in our filings with the SEC and those identified under the section entitled Forward-Looking Statements in the press release that we issued today and filed with the SEC.

With that, I'll turn the call over to Adi. Adi?

Adi Hoess

Thank you, Alex. Good day, everyone and thank you for joining us for our 2022 year-end results and operational update call. I'd like to begin by reviewing the key highlights of 2022, during which we made exciting progress across all our pipeline. Let's jump to Slide 4 of the presentation. And importantly, in 2022, we generated highly compelling results with AFM13 in combination with natural killer cells.